Literature DB >> 17475739

A stepped care strategy using buprenorphine and methadone versus conventional methadone maintenance in heroin dependence: a randomized controlled trial.

Johan Kakko1, Leif Grönbladh, Kerstin Dybrandt Svanborg, Joachim von Wachenfeldt, Christian Rück, Bob Rawlings, Lars-Håkan Nilsson, Markus Heilig.   

Abstract

OBJECTIVE: Both methadone and buprenorphine are effective therapy for heroin dependence. Efficacy is best documented for methadone maintenance therapy, but safety concerns limit its use. Buprenorphine offers lower overdose risk and improved access, but efficacy may be lower. The authors compared adaptive, buprenorphine-based stepped care to optimal methadone maintenance treatment.
METHOD: This randomized controlled trial was undertaken 2004-2006. It consisted of a 24-day uniform double-blind induction phase followed by single-blind flexible dosing based on structured clinical criteria, for a total of 6 months. Ninety-six self-referred subjects with heroin dependence were randomly assigned to methadone or to stepped treatment initiated with buprenorphine/naloxone and escalated to methadone if needed. All subjects received intensive behavioral treatment. Primary outcome was retention in treatment. Secondary outcomes were completer analyses of problem severity (Addiction Severity Index) and proportion of urine samples free of illicit drugs.
RESULTS: Overall, 6-month retention was 78%. Stepped treatment and methadone maintenance therapy outcomes were virtually identical. Among completers of stepped therapy, 46% remained on buprenorphine/naloxone. Proportion of urine samples free of illicit opiates increased over time and ultimately reached approximately 80% in both arms. Problem severity decreased significantly and uniformly in both arms.
CONCLUSIONS: A stepped treatment of heroin dependence as described here appears equally efficacious compared to optimally delivered methadone maintenance therapy. Together with prior data on the advantageous safety of buprenorphine, this suggests that broad implementation of strategies using buprenorphine as first-line treatment should be considered.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17475739     DOI: 10.1176/ajp.2007.164.5.797

Source DB:  PubMed          Journal:  Am J Psychiatry        ISSN: 0002-953X            Impact factor:   18.112


  56 in total

1.  Safety and efficacy of buprenorphine/naloxone in opioid-dependent patients: an Italian observational study.

Authors:  Fernanda Magnelli; Lorita Biondi; Roberto Calabria; Angelo Fiore; Eugenio Peluso; Domenico Vonella; Amerigo Giuseppe Rota
Journal:  Clin Drug Investig       Date:  2010       Impact factor: 2.859

2.  Therapeutic switch to buprenorphine/naloxone from buprenorphine alone: clinical experience in an Italian addiction centre.

Authors:  Franco Montesano; Domenico Zaccone; Egidio Battaglia; Felice Genco; Vincenzo Mellace
Journal:  Clin Drug Investig       Date:  2010       Impact factor: 2.859

3.  The many victims of substance abuse.

Authors:  Tara Mauro
Journal:  Psychiatry (Edgmont)       Date:  2007-09

Review 4.  Pharmacological Management of Opioid Use Disorder in Pregnant Women.

Authors:  Christine M Wilder; Theresa Winhusen
Journal:  CNS Drugs       Date:  2015-08       Impact factor: 5.749

5.  Buprenorphine requires concomitant activation of NOP and MOP receptors to reduce cocaine consumption.

Authors:  Marsida Kallupi; Qianwei Shen; Giordano de Guglielmo; Dennis Yasuda; V Blair Journigan; Nurulain T Zaveri; Roberto Ciccocioppo
Journal:  Addict Biol       Date:  2017-06-21       Impact factor: 4.280

6.  Buprenorphine is a weak partial agonist that inhibits opioid receptor desensitization.

Authors:  Michael S Virk; Seksiri Arttamangkul; William T Birdsong; John T Williams
Journal:  J Neurosci       Date:  2009-06-03       Impact factor: 6.167

7.  A combination of buprenorphine and naltrexone blocks compulsive cocaine intake in rodents without producing dependence.

Authors:  Sunmee Wee; Leandro F Vendruscolo; Kaushik K Misra; Joel E Schlosburg; George F Koob
Journal:  Sci Transl Med       Date:  2012-08-08       Impact factor: 17.956

8.  Buprenorphine treatment for hospitalized, opioid-dependent patients: a randomized clinical trial.

Authors:  Jane M Liebschutz; Denise Crooks; Debra Herman; Bradley Anderson; Judith Tsui; Lidia Z Meshesha; Shernaz Dossabhoy; Michael Stein
Journal:  JAMA Intern Med       Date:  2014-08       Impact factor: 21.873

9.  Opioid Overdose: Risk Assessment and Mitigation in Outpatient Treatment.

Authors:  Lewei Allison Lin; Avinash Hosanagar; Tae Woo Park; Amy S B Bohnert
Journal:  J Addict Med       Date:  2016 Nov/Dec       Impact factor: 3.702

10.  Top manager effects on buprenorphine adoption in outpatient substance abuse treatment programs.

Authors:  Peter D Friedmann; Lan Jiang; Jeffrey A Alexander
Journal:  J Behav Health Serv Res       Date:  2009-03-19       Impact factor: 1.505

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.